BRAF and hepatocellular carcinoma: Sorafenib, a multi-target kinase inhibitor for the treatment of HCC, can directly inhibit tumor growth by blocking BRAF and MAPK signal pathways, previous studies have shown that sorafenib can effectively prolong the median overall survival of patients with advanced hepatocellular carcinoma (76, 77).